Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives

@article{Raps2012SexHG,
  title={Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives},
  author={M. Raps and F. Helmerhorst and K. Fleischer and S. Thomassen and F. Rosendaal and J. Rosing and B. Ballieux and H. van Vliet},
  journal={Journal of Thrombosis and Haemostasis},
  year={2012},
  volume={10}
}
  • M. Raps, F. Helmerhorst, +5 authors H. van Vliet
  • Published 2012
  • Medicine
  • Journal of Thrombosis and Haemostasis
    • Summary.  Background: It takes many years to obtain reliable values for the risk of venous thrombosis of hormonal contraceptive users from clinical data. Measurement of activated protein C (APC) resistance via thrombin generation is a validated test for determining the thrombogenicity of hormonal contraceptives. Sex hormone‐binding globulin (SHBG) might serve as a marker for the risk of venous thrombosis, and can be easily and rapidly measured in routine laboratories. 
    View on Wiley
    ncbi.nlm.nih.gov
    61 Citations
    Highly Influential Citations
    5
    Background Citations
    12
    Results Citations
    5
    61 Citations
    Citation Type

    Citation Type

    Sex hormone‐binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal
    • 8
    Sex hormone‐binding globulin levels are not causally related to venous thrombosis risk in women not using hormonal contraceptives
    • 21
    Sex hormone-binding globulin and thrombin generation in women using hormonal contraception
    • 5
    • Highly Influenced
    Thyroid function, activated protein C resistance and the risk of venous thrombosis in users of hormonal contraceptives.
    • 11
    Thrombotic Risk of Contraceptives and Other Hormonal Therapies
    Oral Contraceptives and HRT Risk of Thrombosis
    • 16
    • Highly Influenced
    Endogenous sex hormones and risk of venous thromboembolism in young women
    • 4
    The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI.
    • 22
    • PDF
    Epidemiology of hormonal contraceptives-related venous thromboembolism.
    • 47
    • PDF
    Unique Vascular Benefits of Estetrol, a Native Fetal Estrogen with Specific Actions in Tissues (NEST)
    • 1

    References

    SHOWING 1-10 OF 45 REFERENCES
    Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills?
    • 142
    Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives.
    • 16
    Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives.
    • 22
    Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate
    • 46
    Estrogens, progestogens and thrombosis
    • 160
    Effects of Oral and Transdermal Hormonal Contraception on Vascular Risk Markers: A Randomized Controlled Trial
    • 66
    The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
    • 376
    • PDF
    Activated protein C resistance determined with a thrombin generation‐based test predicts for venous thrombosis in men and women
    • 130
    The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC).
    • 23
    Hormone therapies and venous thromboembolism: where are we now?
    • 54
    • PDF